Engene Holdings INC

enGene Therapeutics Inc. has released an updated corporate presentation on July 17, 2026, detailing the progress of its lead investigational drug, detalimogene voraplasmid, for Non-Muscle Invasive Bladder Cancer (NMIBC).

enGene Therapeutics announces board leadership changes and outlines upcoming regulatory and commercial plans for its lead drug candidate, detalimogene.

enGene Therapeutics Inc. files an 8-K/A to update its workforce reduction plan, detailing new equity retention awards and revised cost estimates.

enGene Therapeutics announced a 50% workforce reduction and executive departures to streamline operations and preserve cash while advancing its lead drug candidate, detalimogene.

enGene Therapeutics Inc. reports strong shareholder turnout and overwhelming support for director elections and auditor appointment at its 2026 Annual General Meeting.

enGene Therapeutics announced updated interim clinical data from its Phase 2 LEGEND trial for detalimogene voraplasmid, showing a 54% complete response rate at any time.

enGene Therapeutics Inc. filed its Form 10-Q for the quarter ended April 30, 2026, detailing financial results, strategic updates including a significant workforce reduction, and progress on its lead drug candidate, detalimogene.

enGene Holdings Inc. reported a significant increase in net loss and R&D expenses for the quarter ended July 31, 2025, as it advances its lead bladder cancer therapy, detalimogene, towards a planned 2026 BLA submission.

enGene Holdings Inc. announced a significant increase in net loss and cash burn for the six months ended April 30, 2025, driven by intensified research and development efforts for its lead bladder cancer therapy, detalimogene, while also addressing internal control deficiencies and expanding its executive team.

enGene Holdings Inc. reports increased R&D spending as it advances its detalimogene program for bladder cancer treatment.

enGene Holdings Inc. reports a net loss of $14.1 million for the three months ended July 31, 2024, driven by increased research and development spending.

enGene Holdings Inc. reports a significant increase in operating expenses, primarily driven by research and development activities, while highlighting progress in its EG-70 clinical trial.

enGene Holdings Inc. filed an Amendment No. 1 to its Annual Report on Form 10-K to include previously omitted Part III information regarding corporate governance and executive compensation.

enGene Holdings Inc. reported increased net losses for fiscal year 2025 while advancing its lead bladder cancer therapy, detalimogene, towards a planned BLA submission in late 2026.

enGene Holdings Inc. files an amendment to its annual report on Form 10-K to include previously omitted Part III information regarding directors, executive officers, and corporate governance.

enGene Holdings Inc. released its annual 10-K filing, detailing its clinical progress with detalimogene, financial status, and strategic direction.

enGene Holdings Inc. provides a detailed overview of its share capital, warrants, and corporate governance structure in its latest 10-K filing.

Director Philip Astley-Sparke was granted 31,000 stock options in enGene Therapeutics Inc. as part of a standard equity compensation arrangement.

Director Gerald A. Brunk was granted 31,000 stock options in enGene Therapeutics Inc. as part of standard equity compensation.

Director Richard M. Glickman was granted 31,000 stock options in enGene Therapeutics Inc. as part of a standard equity compensation arrangement.

Interim Chief Medical Officer William Grossman was granted 231,000 stock options by enGene Therapeutics Inc. on June 16, 2026.

Director Paul Hastings was granted 31,000 stock options in enGene Therapeutics Inc. as part of a standard equity incentive.

Director Michael Heffernan was granted 31,000 stock options in enGene Therapeutics Inc. as part of a standard equity compensation arrangement.

enGene Therapeutics Inc. announced its upcoming virtual Annual General Meeting on June 9, 2026, where shareholders will vote on director elections, auditor appointment, and review 2025 financial statements.

enGene Holdings Inc. has announced its annual general meeting of shareholders to be held on June 10, 2025, in a virtual format, to vote on key proposals including the election of directors, approval of an employee stock purchase plan, and appointment of auditors.

enGene Holdings Inc. is set to hold its Annual General Meeting on May 15, 2024, featuring proposals including the election of directors and an amendment to the Incentive Equity Plan.

enGene Holdings updates its S-1 registration to facilitate the resale of common shares and warrants by selling securityholders, including those from PIPE financings and legacy investors.

Acorn Bioventures, L.P., Acorn Capital Advisors GP, LLC, Acorn Bioventures 2, L.P., Acorn Capital Advisors GP 2, LLC, and Anders Hove have collectively reported beneficial ownership of 5.0% of enGene Therapeutics Inc. common shares.

Cormorant Asset Management, LP and Bihua Chen have filed a Schedule 13G, reporting no beneficial ownership of enGene Holdings Inc. common shares as of March 31, 2026.

BML Investment Partners, L.P. has disclosed a beneficial ownership of 9.95% of enGene Holdings Inc.'s common shares, as per a Schedule 13G filing.

BML Investment Partners, L.P. has filed a Schedule 13G reporting a 7.8% beneficial ownership stake in enGene Holdings Inc.

Invus Public Equities, L.P. and affiliated entities have reported beneficial ownership of 7.8% of enGene Therapeutics Inc. common shares as of March 31, 2026.

Cormorant Asset Management, LP and Bihua Chen have reported a 5.97% beneficial ownership stake in enGene Holdings Inc. common shares.